Best of BS Opinion: Covid-19 vaccine, promise of techno-nationalism & more

Here's a selection of Business Standard opinion pieces for the day

economic recovery, revival, economy, growth, gdp, market
Illustration: Binay Sinha
Kanika Datta New Delhi
2 min read Last Updated : Jan 05 2021 | 6:45 AM IST
A day after the Indian drug regulator’s announcement that it has approved Covid-19 vaccines manufactured by the Serum Institute and Bharat Biotech, serious questions have been raised regarding the transparency and credibility of the approval process. The top edit sets out some of the anomalies experts have raised suggesting that greater transparency is vital to forestall widespread mistrust in the vaccine, defeating the very purpose of this fast-tracked approval for a rapid return to normalcy. Read it here
 
Other views examine the assumptions in Budget-making this year, India’s rising techno-nationalism and the implications of economic coalitions with China.
 
As state and central governments finalise their FY22 budgets, how much higher should they assume FY22 will be over FY20, the last “normal” year before the pandemic? Neelkanth Mishra sets out the challenges in making those assessments. Read it here
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusBS OpinionCurated ContentCoronavirus VaccineNationalismTechnologyIndian EconomyBharat BiotechSerum Institute of IndiaBudgetUS ChinaEuropean UnionChina

Next Story